Koninklijke Philips N.V. (PHG) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 18.30 means the share price is 18.30 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $24.0B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerKoninklijke Philips N.V. (PHG) trades at $24.60 with MoonshotScore 74/100 (Grade A). Koninklijke Philips N.V. is a global health technology company focused on diagnostic imaging, connected care, and personal health solutions. Market cap: $24.0B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: May 9, 2026PHG stock analysis for 2026: The stored analyst price target for Koninklijke Philips N.V. is $33.74; its date is unknown, so no upside or downside is derived from it against the current price of $24.60. The AI MoonshotScore is 74/100, in the Strong band (65-79) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
These figures come from statements filed 12 months ago — the most recent this company has published.
PHG: 3/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Strongest side: Business Quality (8/10, Strong). Weakest side: Momentum (4/10, Neutral).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Koninklijke Philips N.V. (PHG) Healthcare & Pipeline Overview
Koninklijke Philips N.V. is a diversified health technology company providing diagnostic imaging, connected care, and personal health solutions. With a global presence and a focus on innovation, Philips competes in the medical devices industry against companies like Teva Pharmaceutical Industries and DexCom, Inc., addressing evolving healthcare needs with a comprehensive product portfolio.
What Is the Investment Thesis for PHG?
With a market capitalization of $24.0B and a P/E ratio of 18.30, Philips demonstrates financial stability and profitability, supported by a gross margin of 45.2% and a profit margin of 5.5%. A key value driver is the company's innovation in diagnostic imaging and connected care, addressing the increasing demand for advanced healthcare technologies. Growth catalysts include strategic partnerships and expansion into emerging markets. However, potential risks include regulatory changes and competition from established players like Mettler-Toledo International Inc. and Teva Pharmaceutical Industries Limited. The company's dividend yield of 3.68% provides an additional incentive for investors.
Based on FMP financials and quantitative analysis
PHG Key Highlights
Market capitalization of $24.0B reflects substantial investor confidence in Philips' market position.
- P/E ratio of 18.30 indicates a reasonable valuation relative to earnings.
- Gross margin of 45.2% demonstrates efficient cost management and strong pricing power.
- Profit margin of 5.5% signifies profitability in a competitive industry.
- Dividend yield of 3.68% provides a steady income stream for investors.
Who Are PHG's Competitors?
PHG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| NTRA Natera, Inc. | $326.14 | -1.26% | $46.7B | 395-pillar |
| MTD Mettler-Toledo International Inc. | $1291.99 | +0.89% | $26.1B | 785-pillar |
| BNTX BioNTech SE | $97.13 | +0.76% | $24.4B | 515-pillar |
| DXCM DexCom, Inc. | $84.51 | +0.75% | $31.9B | 885-pillar |
| FUJIF FUJIFILM Holdings Corporation | $20.00 | -0.60% | $23.9B | 489-signal |
| SMMNY Siemens Healthineers AG | $22.18 | -0.94% | $24.8B | 449-signal |
| STE STERIS plc | $212.45 | -1.23% | $20.7B | 855-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are PHG's Key Strengths?
Diversified portfolio of health technology solutions.
- Strong brand recognition and global presence.
- Extensive research and development capabilities.
- Strategic partnerships and collaborations.
What Are PHG's Weaknesses?
Exposure to regulatory risks and compliance requirements.
- Dependence on healthcare spending and reimbursement policies.
- Competition from established and emerging players.
- Product recalls and safety concerns.
What Could Drive PHG Stock Higher?
Expansion of digital health solutions and remote patient monitoring capabilities.
- New product launches in diagnostic imaging and personal health segments.
- Strategic partnerships and collaborations to enhance product offerings.
- Regulatory approvals for innovative medical devices in key markets.
What Are the Key Risks for PHG?
Economic downturns and healthcare budget cuts impacting demand.
- Exposure to regulatory risks and compliance requirements.
- Technological obsolescence and disruptive innovations.
- Product recalls and safety concerns.
- Currency fluctuations affecting ADR value.
What Are the Growth Opportunities for PHG?
- Expansion in Emerging Markets: Philips has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America, where healthcare infrastructure is rapidly developing. These regions present a large and growing demand for diagnostic imaging and connected care solutions. By leveraging its existing partnerships and establishing new distribution channels, Philips can capitalize on this growth, potentially increasing revenue by 15-20% over the next five years.
- Strategic Partnerships and Collaborations: Philips' strategic collaboration with Ibex Medical Analytics Ltd. to promote digital pathology and AI solutions represents a significant growth opportunity. By partnering with innovative companies, Philips can enhance its product offerings and expand its market reach. Further collaborations in areas such as remote patient monitoring and telehealth could drive additional growth, contributing to a 10-15% increase in revenue within three years.
- Innovation in Diagnostic Imaging: The demand for advanced diagnostic imaging solutions is increasing, driven by the need for early and accurate disease detection. Philips' focus on developing innovative technologies, such as detector-based spectral CT solutions and advanced MRI systems, positions it to capture a larger share of the market. Investments in R&D and strategic acquisitions in this area could result in a 20-25% growth in the diagnostic imaging segment over the next five years.
- Connected Care Solutions for Remote Patient Monitoring: The market for remote patient monitoring is expanding due to the increasing prevalence of chronic diseases and the need for cost-effective healthcare delivery. Philips' connected care solutions, including sleep and respiratory care devices and electronic medical record systems, are well-positioned to address this demand. By expanding its remote monitoring capabilities and integrating AI-driven analytics, Philips can achieve a 15-20% growth in this segment over the next three years.
- Personal Health Products and Digital Parental Solutions: Philips' personal health segment, which includes power toothbrushes, infant feeding solutions, and male grooming products, offers a stable and growing revenue stream. The increasing consumer focus on health and wellness, coupled with the rise of digital parental solutions, presents opportunities for Philips to expand its market share. By launching innovative products and leveraging digital marketing strategies, Philips can achieve a 10-15% growth in this segment over the next five years.
What Threats Does PHG Face?
- Economic downturns and healthcare budget cuts.
- Technological obsolescence and disruptive innovations.
- Cybersecurity threats and data breaches.
- Geopolitical instability and trade barriers.
What Are PHG's Competitive Advantages?
- Strong brand reputation and global presence.
- Extensive portfolio of patented technologies and intellectual property.
- Established relationships with key customers and partners.
- Significant investment in research and development.
- Comprehensive service and support network.
What Does PHG Do?
Koninklijke Philips N.V., founded in 1891 in Amsterdam, Netherlands, has evolved from a lighting company to a global leader in health technology. Initially focused on manufacturing light bulbs, Philips expanded into consumer electronics and, eventually, healthcare solutions. This strategic shift culminated in the company changing its name from Koninklijke Philips Electronics N.V. to Koninklijke Philips N.V. in May 2013, reflecting its commitment to the health technology sector. Today, Philips operates through three primary business segments: Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses. The Diagnosis & Treatment segment offers advanced imaging solutions like MRI, CT, and X-ray systems, along with interventional systems and diagnostic informatics. The Connected Care segment provides solutions for acute patient management, emergency care, and sleep and respiratory care. The Personal Health segment focuses on consumer products such as power toothbrushes, infant feeding solutions, and male grooming products. Philips has a global presence, serving markets in North America and internationally. Strategic collaborations, such as those with Ibex Medical Analytics and NICO.LAB, enhance its offerings in digital pathology and AI-driven healthcare solutions. With a workforce of 67,247 employees, Philips continues to innovate and adapt to the changing landscape of healthcare technology.
What Products and Services Does PHG Offer?
- Develops and markets diagnostic imaging solutions, including MRI, CT, and X-ray systems.
- Provides connected care solutions for acute patient management and emergency care.
- Offers sleep and respiratory care solutions for patients with sleep disorders and respiratory conditions.
- Manufactures and sells personal health products, such as power toothbrushes and infant feeding solutions.
- Provides electronic medical record and care management solutions for healthcare providers.
- Offers molecular and hybrid imaging solutions for nuclear medicine.
- Provides integrated interventional systems for minimally invasive procedures.
How Does PHG Make Money?
- Sells diagnostic imaging equipment and related services to hospitals and clinics.
- Provides connected care solutions through a combination of hardware, software, and services.
- Generates revenue from the sale of personal health products through retail channels and online platforms.
- Offers maintenance and support services for its installed base of medical equipment.
- Collaborates with healthcare providers and research institutions to develop new technologies and solutions.
What Industry Does PHG Operate In?
Koninklijke Philips N.V. operates within the rapidly evolving medical devices industry, characterized by technological advancements, increasing demand for healthcare services, and stringent regulatory requirements. Philips competes with major players like Mettler-Toledo International Inc. and DexCom, Inc., focusing on innovation and strategic partnerships to maintain its competitive edge. The industry is also witnessing a shift towards digital health solutions and AI-driven diagnostics, presenting both opportunities and challenges for companies like Philips.
Who Are PHG's Key Customers?
- Hospitals and clinics
- Healthcare providers
- Individual consumers
- Research institutions
- Government healthcare agencies
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 100% of our measures
- ● Price is current
- ● Latest filing 45 days ago
- ● Covered by analysts
- ● Reported in EUR, converted to USD
Why 74?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.54 Financial-health checklist (Financial Strength)
- +0.40 Gross profit per dollar of assets (Business Quality)
- +0.39 Return on equity (Business Quality)
What is holding it back
- -0.54 Debt to equity (Financial Strength)
- -0.48 5-year net income per share (Growth)
- -0.19 Net debt vs earnings (Financial Strength)
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 44 |
| 2026-08-26 | 44 |
| 2026-08-29 | 44 |
| 2026-09-01 | 73 |
| 2026-09-04 | 73 |
| 2026-09-07 | 74 |
| 2026-09-10 | 74 |
What changed?
The grade moved from 44 to 74 (+30).
Over the same 18 days the stock moved -9.8%.
Koninklijke Philips N.V. (PHG) Valuation Context
Valued at $24.0B, PHG is classified as a large-cap stock. Relative to its peer group, PHG's quantitative score of 74/100 is above the peer average of 62/100.
PHG Revenue & Earnings Trend
In Q2 FY2026, PHG generated $5.06B in top-line revenue, marking a sequential increase of 11.7%. The company recorded net income of $445.5M, with diluted EPS of $0.46. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, PHG averaged $0.33 in diluted EPS.
Company Profile
Koninklijke Philips N.V. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Amsterdam, NL. The company is led by CEO Roy W. O. Jakobs. PHG has traded publicly since 1980.
Key Financial Metrics
Return on equity for Koninklijke Philips N.V. stands at 10.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.2%, showing how much profit it generates from its asset base. PHG trades at a trailing price-to-earnings ratio of 18.30, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Koninklijke Philips N.V.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.96 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Koninklijke Philips N.V. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 24.9% above estimates on average.
PHG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified portfolio of health technology solutions.
- Strong brand recognition and global presence.
- Extensive research and development capabilities.
- Strategic partnerships and collaborations.
Bear Case
- Exposure to regulatory risks and compliance requirements.
- Dependence on healthcare spending and reimbursement policies.
- Competition from established and emerging players.
- Product recalls and safety concerns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5.06B | $446M | $0.46 |
| Q1 FY2026 | $4.53B | $175M | $0.18 |
| Q4 FY2025 | $5.91B | $458M | $0.47 |
| Q3 FY2025 | $4.99B | $213M | $0.22 |
Q2 FY2026 · filed 28 Jul 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
PHG Latest News
-
1 Cash-Producing Stock to Research Further and 2 Facing Challenges
StockStory · Sep 10, 2026
-
MRI Systems Market Forecast: $9.68 Billion by 2031 – MarketsandMarkets™
Yahoo! Finance: PHG News · Sep 9, 2026
-
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
Yahoo! Finance: PHG News · Sep 8, 2026
-
Philips Launches Revolutionary Lumea® IPL 9900 Pro: the First At-Home Intense Pulsed Light (IPL) Hair Removal Device With Real-Time Audio Guidance That Talks to You During Treatment
businesswire.com · Sep 8, 2026
PHG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PHG.
Price Targets
Consensus target: $33.74
PHG MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. PHG scores 74/100 (Grade A): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
1 Cash-Producing Stock to Research Further and 2 Facing Challenges
MRI Systems Market Forecast: $9.68 Billion by 2031 – MarketsandMarkets™
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
Philips Launches Revolutionary Lumea® IPL 9900 Pro: the First At-Home Intense Pulsed Light (IPL) Hair Removal Device With Real-Time Audio Guidance That Talks to You During Treatment
Leadership: Roy W. O. Jakobs
Chief Executive Officer
Roy Jakobs serves as the Chief Executive Officer of Koninklijke Philips N.V. His career within Philips spans several leadership roles, demonstrating a deep understanding of the company's operations and strategic direction. Prior to becoming CEO, he held key positions in various business segments, including leading the Connected Care businesses. His experience encompasses a broad range of responsibilities, from product development and marketing to sales and operations. He is known for his focus on innovation, customer-centricity, and driving sustainable growth.
Track Record: Since assuming the role of CEO, Roy Jakobs has focused on streamlining Philips' operations and accelerating its transformation into a leading health technology company. Key milestones under his leadership include strategic partnerships to expand the company's digital health offerings and initiatives to improve operational efficiency. He has also overseen efforts to address product quality issues and enhance customer satisfaction. His leadership is characterized by a commitment to innovation, sustainability, and creating long-term value for shareholders.
Koninklijke Philips N.V. ADR Information
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company, allowing U.S. investors to trade the stock on American exchanges. For Koninklijke Philips N.V. (PHG), each ADR represents a specific number of ordinary shares traded on its home exchange in Amsterdam. This facilitates U.S. investment without the complexities of cross-border transactions.
- Home Market Ticker: Euronext Amsterdam, Netherlands
What Investors Ask About Koninklijke Philips N.V. (PHG) — Healthcare
What does the AI Score mean for PHG?
PHG holds an AI Score of 74/100 (Grade: A). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Koninklijke Philips N.V. is a global health technology company focused on diagnostic imaging, connected care, and personal health solutions.
Is PHG a good stock?
Stock Expert AI does not rate PHG buy, sell or hold. Koninklijke Philips N.V. carries a MoonshotScore of 74/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Koninklijke Philips N.V. do?
Koninklijke Philips N.V. is a global health technology company that focuses on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care.
What are the key factors to evaluate for PHG?
Koninklijke Philips N.V. (PHG) holds a MoonshotScore of 74/100 (high). P/E: 18.30x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does PHG data refresh on this page?
PHG's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PHG's recent stock price performance?
Koninklijke Philips N.V. (PHG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified portfolio of health technology solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHG overvalued or undervalued right now?
Koninklijke Philips N.V. (PHG) trades at 18.30x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PHG?
Yes, most major brokerages offer fractional shares of Koninklijke Philips N.V. (PHG) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track PHG's earnings and financial reports?
Koninklijke Philips N.V. (PHG) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for PHG earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest reporting period.